
|Articles|August 12, 2013
Mechanism of Action: Nintedanib (BIBF 1120)
Nintedanib (also known as Vargatef and BIBF 1120) is an oxindole-based, orally-available triple kinase inhibitor targeting the angiogenesis factors VEGF, PDGF, and FGF.
Advertisement
Nintedanib (also known as Vargatef and BIBF 1120) is an oxindole-based, orally-available triple kinase inhibitor targeting the angiogenesis factors vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), and fibroblast growth factor (FGF).
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
3 Trials Refine Endocrine, HER2-Targeted Therapies at SABCS
2
Exploring Radiation Therapy’s Reach in Prostate Cancer
3
FDA Grants Breakthrough Therapy Designation to Sofi-Cel for R/R T-ALL/LBL
4
BNT113 Garners Fast-Track Designation in PD-L1+ HPV16+ HNSCC
5














































